[Clinical studies on the choleretic agent Febuprol (author's transl)].
In previous pharmacological experiments with the choleretic agent Febuprol, healthy subjects showed a significant increase in bile flow and its constituents in the acute experiment. As a consequence of these results we have carried out a double-blind cross-over therapeutic trial with Febuprol in 50 patients with a cholecystopathic symptom complex. After a 14 days' treatment (3 capsules daily) a significant improvement of the typical symptoms (feeling of fullness, pressure in the upper abdomen, meteorism, constipation, flatulence and nausea after food) was recorded in these patients. Moreover a significant lowering of the serum cholesterol level was noteworthy.
D000433:1-Propanol / Q000494:pharmacology; D000328:Adult; D000368:Aged; D001647:Bile Acids and Salts / Q000378:metabolism; D002756:Cholagogues and Choleretics / Q000627:therapeutic use*; D002764:Cholecystitis / Q000188:drug therapy; D002784:Cholesterol / Q000097:blood; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004341:Drug Evaluation; D004386:Duodenum / Q000378:metabolism; D005260:Female; D005705:Gallbladder Diseases / Q000188:drug therapy*; D006801:Humans; D007419:Intestinal Secretions / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D010919:Placebos; D020005:Propanols
D001647:Bile Acids and Salts; D002756:Cholagogues and Choleretics; D010919:Placebos; D020005:Propanols; D000433:1-Propanol; D002784:Cholesterol
Klinische Untersuchungen über das Choleretikum Febuprol.